SecBot SecBot

AMRX

Amneal Pharmaceuticals, Inc.
Nasdaq· Pharmaceutical Preparations· CIK 0001723128 Biotech & Drug Discovery
$21.26 +0.24 (+1.14%)
Oct 27 4:00 PM ET · prev $21.02
Market cap
$7.1B
Mid cap
Consensus
Buy
92% Buy or better · 13 analysts
Median target
$23.00
+8% · range $20.00–27.00
Next earnings
Nov 3
in 7 days
1 year
+107.4%
from $10.25 · Oct 27
30 days
+3.7%
from $20.50
52-week range
$10.00–21.26
at the high
Avg volume 20D
3.94M
shares / day
Short interest
🔒 Subscribers only
Insider net
−$7.7M
0 buyers · 4 sellers · since Mar 3
New fund stakes
1
Q2 2026 13F · 0 exits
Filing reports
14
analyzed by SecBot
SecBot read MIXED 7 reports · 90 days
Balance 1 bearish · 2 bullish · 2 mixed · 2 neutral oldest → newest, height = score
Avg score ·High conf. 4/7 ·Next Earnings date, Nov 3, 2026
Strongest NEUTRAL Amneal Pharmaceuticals filed an 8-K/A providing unaudited pro forma financial statements for its acquisition…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $7.7M.

  • InstitutionsBULLISH

    Q2 2026: 30 added (1 new), 11 trimmed or exited. Largest new: Congress Asset Management $13.5M.

  • AnalystsBULLISH

    12 of 13 rate it Buy or better. Median target $23.00 (+8%).

  • TrendUPTREND

    12% above its 50-day average. New closing high $21.26 on Oct 27.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$13.5M
in new stakes
FundMoveSharesValue
Allspring Global Investments Holdings, LLCADD3,295,533$55.9M
CITADEL ADVISORS LLCADD1,118,715$19.4M
CONGRESS ASSET MANAGEMENT CONEW782,778$13.5M
D. E. Shaw & Co., Inc.TRIM774,055$13.4M
Pictet Asset Management Holding SADOUBLED611,230$10.6M
UBS Group AGTRIM444,400$7.7M
BALYASNY ASSET MANAGEMENT L.P.DOUBLED434,132$7.5M
WELLS FARGO & COMPANY/MNDOUBLED422,395$7.3M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts
Buy 92% rate it Buy or better
Strong Buy5Buy7Hold1Sell0Strong Sell0
12-month targets · 7 analysts

Price is inside the target range. Median implies +8%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 22, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Sep 23, 2026Oppenheimer
INITIATE
INITIATEOutperform
Sep 17, 2026Barclays
MAINTAIN
MAINTAINOverweight
Sep 9, 2026Leerink Partners
INITIATE
INITIATEOutperform
Aug 3, 2026UBS
MAINTAIN
MAINTAINBuy
Jul 15, 2026UBS
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$7.7M
sold · 4 insiders
DateInsiderTypeValue
Sep 17, 2026
BUCHI J KEVIN
Director
GIFT20,445 sh
Sep 11, 2026
BUCHI J KEVIN
Director
EXERCISE$295.4K
Sep 1, 2026
BOYER ANDREW S
Executive Vice President
GIFT80,000 sh
Aug 21, 2026
BOYER ANDREW S
Executive Vice President
GIFT152,426 sh
Aug 13, 2026
Kiely John
Director
GIFT10,000 sh
Aug 13, 2026
Kiely John
Director
SELL$882.0K
Aug 12, 2026
Shah Nikita
Executive Vice President
SELL$2.6M
Aug 12, 2026
Daly Jason B.
EVP, Chief Legal Officer
SELL$3.7M

Earnings setup

Estimates
Nov 3
reports in 7 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

27 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 23, 2026 SEC
Amneal Pharmaceuticals filed an 8-K/A providing unaudited pro forma financial statements for its acquisition of Kashiv…
8-K/A — Impact 5/10
Oct 15, 2026 Short interest report
🔒 Fresh data, subscribers only
Oct 7, 2026 Event
Estradiol Gel, 0.1%, 0.25 mg, 30-packets per carton, Rx only, Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08907, NDC 69238-2452-3.
Class II: Defective Container; packets were found to be either empty or partially full.
Sep 18, 2026 Press
Amneal Pharmaceuticals received FDA approval for its lanreotide injection (120 mg/0.5 mL), a generic version of…
Impact 6/10
Sep 17, 2026 Insider
BUCHI J KEVIN gifted 20,445 shares
Director
Sep 11, 2026 Insider
BUCHI J KEVIN acquired via exercise 20,445 shares
Director @ $14.45 ($295.4K)
Sep 1, 2026 Insider
BOYER ANDREW S gifted 80,000 shares
Executive Vice President
Aug 16, 2026 SEC
A strong institutional accumulation cluster emerged in Amneal Pharmaceuticals during 2026-Q2, with 14 buyers adding a…
INST-CLUSTER — Impact 6/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 3, 2026
Earnings date
AMRX Q3 2026 Earnings Scheduled — 2026-11-03
Recent
Oct 15, 2026
Short interest
🔒 Fresh data, subscribers only
Oct 7, 2026
FDA
Estradiol Gel, 0.1%, 0.25 mg, 30-packets per carton, Rx only, Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08907, NDC 69238-2452-3.
Class II: Defective Container; packets were found to be either empty or partially full.
Sep 30, 2026
FDA
Exenatide Injection, USP, 250 mcg/mL, 1.2 mL per prefilled pen, Rx Only, Subcutaneous Use Only, For Single Patient Use Only, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd., Ahmedabad 382213, India; Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807, NDC 70121-1685-1
Class II: Defective Delivery System: Possibility of no medication in the prefilled pen.
Sep 18, 2026
FDA
Amneal Announces FDA Approval and Launch of Lanreotide Injection
- Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production
Aug 28, 2026
FDA
Lisdexamfetamine Dimesylate
WARNING: ABUSE, MISUSE, AND ADDICTION Lisdexamfetamine dimesylate has a high potential for abuse and misuse, which can lead to the development of a su

SecBot reports

14 filings · 3 press releases · 5 bullish · 1 bearish · 3 mixed · 5 neutral
All AMRX filing & press-release reports (17)